TB/Flu-06E
The vaccine platform is based on the live influenza virus vector that is highly attenuated through alteration in NS1 protein function. This effect is achieved by the replacement of immunosuppressive C-terminal part of NS1 open reading frame with foreign sequences, encoding ESAT-6 antigen of M. tuberculosis. Importantly, viral vector itself acts as an adjuvant, stimulating…
Read MorerAd-Rv2299c
rAd-Rv2299c is a chimpanzee adenovirus-vectored vaccine expressing Rv2299c. Constructed using pRSK17 shuttle plasmid, packaged in HEK293A cells, and purified by cesium chloride density centrifugation. Formulated for intranasal inhalation at 1×10⁸ PFU/50 μL PBS. The platform exhibits low human seroprevalence with trained immunity induction in DCs. No exogenous adjuvants.
Read MoreREA
A multifusion protein-based vaccine formulated with MPL/DDA.
Read MorepcDNA3.1-rpfB, pcDNA3.1-rpfD
The candidate vaccine we are developing is a recombinant plasmid DNA vaccine. Two genes from the rpfs family, namely rpfB and rpfD, were inserted full-length into the pcDNA3.1 plasmid along with the Kozak sequence, resulting in recombinant plasmids pcDNA3.1-rpfB and pcDNA3.1-rpfD. The vaccination method used on test animals is intramuscular injection of the recombinant plasmid…
Read MoreBCG-STING
BCG-STING is a recombinant BCG strain that overexpresses the small molecule STING agonist cyclic di-AMP. For prevention of Mtb proliferation BCG-STING is more potent than standard BCG in mouse, guinea pig, and NHP models, and it is also safer than BCG-WT in mouse models. BCG-STING can be produced by fermentation, overcoming current BCG production limitations.
Read More